First Patient Dosed in EQ504 Phase 1, Unlocking $20M Milestone Tranche
EQ sits 48% above its 52-week low of $0.756.
Summary
Equillium dosed the first subject in Australia in the Phase 1 trial of EQ504, its oral colon-targeted AhR modulator for inflammatory disease. That dosing event triggers the milestone closing of $20 million under the August 2025 equity private placement: 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669, bringing total placement proceeds to roughly $50 million. The raise is priced well below the current $1.12 share price, so dilution is real, but it extends cash runway into 2029 and removes near-term financing risk. The study is a randomized, double-blind, placebo-controlled trial in about 70 healthy subjects with doses of 0.1–3.0 mg, including GI mucosal biopsies measuring CYP1A1 as a marker of target engagement. Topline Phase 1 proof-of-mechanism data are expected in Q2 2027, with a placebo-controlled proof-of-concept study in ulcerative colitis planned for the second half of 2027.
At the time of this announcement, EQ was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78M. The 52-week trading range was $0.76 to $3.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.